Natural Capsules DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025


0.90×	0.88×	0.22×
1.54×	1.49×	0.33×
−9.4%	−10.0%	5.0%
0.44×	0.44×	0.40×
1.81×	1.81×	1.63×
−10.4%	−10.5%	0.2%
−7.5%	−7.5%	0.3%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NATCAPSUQ₹136.44

Natural Capsules Limited

· Pharma & Health

₹ CrorePeersNECLIFE AAREYDRUGS BALPHARMA ALPA KREBSBIO MEDICAMEQ MEDICO VINEETLABMcap ₹142 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.22	0.88	0.90
Interest Burden (Pretax/EBIT) ×	0.33	1.49	1.54
EBIT Margin %	4.96	-9.99	-9.45
Asset Turnover ×	0.40	0.44	0.44
Financial Leverage (Assets/Equity) ×	1.63	1.81	1.81
ROE (5-step product, year-end total equity) %	0.24	-10.48	-10.35
ROE (owners' profit / average owners' equity) %	0.27	-7.51	-7.51

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.